These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25060751)

  • 1. Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas.
    Trottier M; Lunn J; Butler R; Curling D; Turnquest T; Royer R; Akbari MR; Donenberg T; Hurley J; Narod SA
    Clin Genet; 2015 Aug; 88(2):182-6. PubMed ID: 25060751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas.
    Trottier M; Lunn J; Butler R; Curling D; Turnquest T; Francis W; Halliday D; Royer R; Zhang S; Li S; Thompson I; Donenberg T; Hurley J; Akbari MR; Narod SA
    Clin Genet; 2016 Mar; 89(3):328-31. PubMed ID: 25920394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
    Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
    Nilsson MP; Törngren T; Henriksson K; Kristoffersson U; Kvist A; Silfverberg B; Borg Å; Loman N
    Breast Cancer Res Treat; 2018 Feb; 168(1):117-126. PubMed ID: 29164420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
    Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
    Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
    DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
    Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic testing for BRCA1 and BRCA2 in the Province of Ontario.
    Finch A; Wang M; Fine A; Atri L; Khalouei S; Pupavac M; Rosen B; Eisen A; Elser C; Charames G; Metcalfe K; Chang MC; Narod SA; Lerner-Ellis J
    Clin Genet; 2016 Mar; 89(3):304-11. PubMed ID: 26219728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas.
    Akbari MR; Donenberg T; Lunn J; Curling D; Turnquest T; Krill-Jackson E; Zhang S; Narod SA; Hurley J
    Clin Genet; 2014 Jan; 85(1):64-7. PubMed ID: 23458327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finding all BRCA pathogenic mutation carriers: best practice models.
    Hoogerbrugge N; Jongmans MC
    Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S19-26. PubMed ID: 27514840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.
    Zuradelli M; Peissel B; Manoukian S; Zaffaroni D; Barile M; Pensotti V; Cavallari U; Masci G; Mariette F; Benski AC; Santoro A; Radice P
    Breast Cancer Res Treat; 2010 Nov; 124(1):251-8. PubMed ID: 20373018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
    De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
    Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing participation in BRCA1/2-positive families: initiator role of index cases.
    Blandy C; Chabal F; Stoppa-Lyonnet D; Julian-Reynier C
    Genet Test; 2003; 7(3):225-33. PubMed ID: 14658447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes.
    Akbari MR; Zhang S; Fan I; Royer R; Li S; Risch H; McLaughlin J; Rosen B; Sun P; Narod SA
    J Med Genet; 2011 Nov; 48(11):783-6. PubMed ID: 21965345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study.
    Nilsson MP; Nilsson ED; Borg Å; Brandberg Y; Silfverberg B; Loman N
    Breast Cancer Res Treat; 2019 Jan; 173(2):313-318. PubMed ID: 30311024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.
    Høberg-Vetti H; Bjorvatn C; Fiane BE; Aas T; Woie K; Espelid H; Rusken T; Eikesdal HP; Listøl W; Haavind MT; Knappskog PM; Haukanes BI; Steen VM; Hoogerbrugge N
    Eur J Hum Genet; 2016 Jun; 24(6):881-8. PubMed ID: 26350514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
    Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
    Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas.
    Donenberg T; Lunn J; Curling D; Turnquest T; Krill-Jackson E; Royer R; Narod SA; Hurley J
    Breast Cancer Res Treat; 2011 Jan; 125(2):591-6. PubMed ID: 20838878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.